Source:http://linkedlifedata.com/resource/pubmed/id/19740565
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2010-5-4
|
| pubmed:abstractText |
The purpose of this phase I/II study is to evaluate a new combination chemotherapy consisting of docetaxel and S-1 as front-line therapy for patients with untreated advanced non-small cell lung cancer (NSCLC). The treatment included docetaxel on day 1 and oral S-1 at a fixed dose of 40mg/m(2) administered twice daily on days 1-14 and repeated every 3 weeks. In phase I, docetaxel at escalating doses of 40 (level 0), 50 (level 1) and 60mg/m(2) (level 2) was administered starting from level 1. Because only one patient among the 6-patient cohort at level 1 and no patient among the 3-patient cohort at level 2 experienced defined dose-limiting toxicity (DLT), level 2 was determined as the recommended dose. In phase II, 60 patients were treated at the recommended dose for median 3 cycles, and the overall response rate was 30% (95% confidence interval [CI], 18.9-43.2%), and the median overall and progression-free survival times were 15.2 (95% CI: 10.5-17.7) and 4.9 (95% CI: 3.5-5.6) months, respectively. The most frequent toxicities experienced were neutropenia, febrile neutropenia and appetite loss; all toxicities were however well manageable. The present regimen showed a potent activity with mild toxicity in untreated NSCLC.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination),
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1872-8332
|
| pubmed:author | |
| pubmed:copyrightInfo |
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
68
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
409-14
|
| pubmed:meshHeading |
pubmed-meshheading:19740565-Administration, Oral,
pubmed-meshheading:19740565-Adult,
pubmed-meshheading:19740565-Aged,
pubmed-meshheading:19740565-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:19740565-Disease Progression,
pubmed-meshheading:19740565-Drug Combinations,
pubmed-meshheading:19740565-Drug Dosage Calculations,
pubmed-meshheading:19740565-Drug Therapy, Combination,
pubmed-meshheading:19740565-Female,
pubmed-meshheading:19740565-Humans,
pubmed-meshheading:19740565-Lung Neoplasms,
pubmed-meshheading:19740565-Male,
pubmed-meshheading:19740565-Middle Aged,
pubmed-meshheading:19740565-Neoplasm Staging,
pubmed-meshheading:19740565-Neutropenia,
pubmed-meshheading:19740565-Oxonic Acid,
pubmed-meshheading:19740565-Survival Analysis,
pubmed-meshheading:19740565-Taxoids,
pubmed-meshheading:19740565-Tegafur
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer.
|
| pubmed:affiliation |
Department of Respirology (B2), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. takiguchi@faculty.chiba-u.jp
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|